Invion Limited Stock Fundamentals
| 7C8 Stock | EUR 0.14 0.01 6.67% |
Invion Limited fundamentals help investors to digest information that contributes to Invion's financial success or failures. It also enables traders to predict the movement of Invion Stock. The fundamental analysis module provides a way to measure Invion's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Invion stock.
Invion |
Invion Limited Company Shares Outstanding Analysis
Invion's Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Invion Shares Outstanding | 4.21 B |
Most of Invion's fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Invion Limited is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Based on the latest financial disclosure, Invion Limited has 4.21 B of shares currently outstending. This is much higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers - Specialty & Generic industry. The shares outstanding for all Germany stocks is significantly lower than that of the firm.
Invion Limited Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Invion's current stock value. Our valuation model uses many indicators to compare Invion value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Invion competition to find correlations between indicators driving Invion's intrinsic value. More Info.Invion Limited is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Invion's earnings, one of the primary drivers of an investment's value.Invion Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Invion's direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Invion could also be used in its relative valuation, which is a method of valuing Invion by comparing valuation metrics of similar companies.Invion is currently under evaluation in shares outstanding category among its peers.
Invion Fundamentals
| Return On Equity | -81.76 | |||
| Return On Asset | -16.15 | |||
| Operating Margin | (283.07) % | |||
| Current Valuation | 3.37 M | |||
| Shares Outstanding | 4.21 B | |||
| Price To Earning | 3.00 X | |||
| Price To Book | 8.00 X | |||
| Revenue | 545.26 K | |||
| Gross Profit | 307.47 K | |||
| EBITDA | (564.03 K) | |||
| Net Income | (3.6 M) | |||
| Cash And Equivalents | 2.14 M | |||
| Total Debt | 15 K | |||
| Debt To Equity | 0.20 % | |||
| Current Ratio | 1.72 X | |||
| Cash Flow From Operations | 522.62 K | |||
| Earnings Per Share | (0) X | |||
| Beta | 0.26 | |||
| Market Capitalization | 645.52 M |
About Invion Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Invion Limited's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Invion using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Invion Limited based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Invion Limited, a clinical-stage drug development company, develops treatments for inflammatory diseases in Australia and the United States. It has a research and development alliance agreement with Hudson Institute of Medical Research to collaborate on a range of research and development projects for the Photosoft technology for the treatment of a range of cancers. Invion operates under Drug Manufacturers - Specialty Generic classification in Germany and is traded on Frankfurt Stock Exchange. It employs 2 people.
Currently Active Assets on Macroaxis
Other Information on Investing in Invion Stock
Invion financial ratios help investors to determine whether Invion Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Invion with respect to the benefits of owning Invion security.